CoChat

The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations

Agarwala, Anandita, Jones, Peter, Nambi, Vijay · 2015 · Current Atherosclerosis Reports

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Antisense oligonucleotide therapy is a promising approach for the treatment of a broad variety of medical conditions. It functions at the cellular level by interfering with RNA function, often leading to degradation of specifically targeted abnormal gene products implicated in the disease process. Mipomersen is a novel antisense oligonucleotide directed at apolipoprotein (apoB)-100, the primary apolipoprotein associated with low-density lipoprotein cholesterol (LDL-C), which has recently been approved for the treatment of familial hypercholesterolemia. A number of clinical studies have demonstrated its efficacy in lowering LDL-C and apoB levels in patients with elevated LDL-C despite maximal medical therapy using conventional lipid-lowering agents. This review outlines the risks and benefits of therapy and provides recommendations on the use of mipomersen.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-014-0467-4

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 31

Metadata

Authors
Agarwala, A., Jones, P., & Nambi, V.
Affiliations
  • Michael E. DeBakey VA Medical Center (US)
  • Baylor College of Medicine (US)
Corresponding author
Nambi, Vijay
Venue
Current Atherosclerosis Reports
Published
2014-11-15
Volume
17
Issue
1
Pages
467-467
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W2069909233
Cited by
31
References
47
Citations by year
2026: 1 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 6
FWCI
0.44
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
antisense therapy, familial hypercholesterolemia, mipomersen, apolipoprotein B-100, LDL cholesterol lowering, lipid-lowering therapy, treatment risks and benefits, management recommendations
MeSH terms
Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Oligonucleotides, Oligonucleotides, Antisense, Practice Guidelines as Topic, Risk Assessment, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations. https://app.cochat.ai/papers/10.1007/s11883-014-0467-4
The paper
Agarwala, A., Jones, P., & Nambi, V. (2015). The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-014-0467-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.